Menu

Mutated Flu May Dodge Vaccine Protection

About half of the H3N2 influenza samples tested in the United States encode altered antigens from the strain used to produce this year’s vaccine.

Dec 8, 2014
Molly Sharlach

A 3-D print of an influenza virus, showing the surface antigens hemagglutinin (blue) and neuraminidase (red)FLICKR, NIAID

While widespread vaccination is still the best defense against the influenza virus, the US Centers for Disease Control and Prevention (CDC) warned last week (December 4) that many of this year’s circulating strains are different from the ones used to formulate the annual flu vaccine.

So far this season, more than 90 percent of the reported flu cases in the US are of the H3N2 subtype, and 52 percent of the samples tested have mutations in antigen-encoding genes compared to the sample used to produce the annual vaccine.

“They’re different enough that we’re concerned that protection from vaccination against the drifted H3N2 viruses may be lower than we usually see,” CDC Director Thomas Frieden said. “These changes can signal that the immune response provided by vaccination won’t protect as well for these viruses,” he said, but added that the vaccine “may have some effectiveness against the drifted strain,” McClatchy DC reported.

According to a CDC statement, the flu vaccine was 37 percent effective in 2007-2008, when a drift variant also predominated; the overall effectiveness in the U.S. is usually between 50 and 55 percent.

The CDC is recommending that clinicians promptly prescribe antiviral medications to suspected influenza patients, even before a confirmed diagnosis. Early treatment is particularly important for those who are more vulnerable to the virus’s effects, including children under 2, adults over 65, and others with certain medical conditions.

“It’s too early to say for sure that this will be a severe flu season, but Americans should be prepared,” Frieden said in a statement. “We can save lives with a three-pronged effort to fight the flu: vaccination, prompt treatment for people at high risk of complications, and preventive health measures, such as staying home when you’re sick, to reduce flu spread.”

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.